Overview
Hiroko Nakajima practices in Osaka, Japan. Ms. Nakajima is rated as an Advanced expert by MediFind in the treatment of WT1-Related Wilms Tumor Syndromes. Her top areas of expertise are Wilms Tumor, WT1-Related Wilms Tumor Syndromes, Renal Cell Carcinoma (RCC), and Thymic Epithelial Tumor.
Her clinical research consists of co-authoring 44 peer reviewed articles. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 2 articles in the study of WT1-Related Wilms Tumor Syndromes.
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Distinguished
- Wilms TumorMs. Nakajima isDistinguished. Learn about Wilms Tumor.
- Advanced
- WT1-Related Wilms Tumor SyndromesMs. Nakajima isAdvanced. Learn about WT1-Related Wilms Tumor Syndromes.
- Experienced
- AstrocytomaMs. Nakajima isExperienced. Learn about Astrocytoma.
- GlioblastomaMs. Nakajima isExperienced. Learn about Glioblastoma.
- GliomaMs. Nakajima isExperienced. Learn about Glioma.
- Gliomatosis CerebriMs. Nakajima isExperienced. Learn about Gliomatosis Cerebri.
- Hypersensitivity PneumonitisMs. Nakajima isExperienced. Learn about Hypersensitivity Pneumonitis.
- LeukemiaMs. Nakajima isExperienced. Learn about Leukemia.